DE20005297U1 - Active ingredient combination against nicotine addiction - Google Patents
Active ingredient combination against nicotine addictionInfo
- Publication number
- DE20005297U1 DE20005297U1 DE20005297U DE20005297U DE20005297U1 DE 20005297 U1 DE20005297 U1 DE 20005297U1 DE 20005297 U DE20005297 U DE 20005297U DE 20005297 U DE20005297 U DE 20005297U DE 20005297 U1 DE20005297 U1 DE 20005297U1
- Authority
- DE
- Germany
- Prior art keywords
- approx
- choline
- active ingredient
- nicotine addiction
- ingredient combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004480 active ingredient Substances 0.000 title claims description 4
- 206010057852 Nicotine dependence Diseases 0.000 title claims description 3
- 208000025569 Tobacco Use disease Diseases 0.000 title claims description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 7
- 229960001231 choline Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002887 deanol Drugs 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 235000020721 horse chestnut extract Nutrition 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 2
- 235000019743 Choline chloride Nutrition 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229960004874 choline bitartrate Drugs 0.000 claims description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 2
- 229960003178 choline chloride Drugs 0.000 claims description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940101267 panthenol Drugs 0.000 claims 1
- 235000020957 pantothenol Nutrition 0.000 claims 1
- 239000011619 pantothenol Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 9
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 239000002243 precursor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Ludwig Wilhelm Fehling, Stückenberg 43,24226 HeikendorfLudwig Wilhelm Fehling, Stückenberg 43,24226 Heikendorf
-2--2-
Beschreibung
Wirkstofikombination gegen NikotinabhängigkeitDescription
Combination of active ingredients against nicotine addiction
Die meisten "Designer-Foods" von Durk Pearson und Sandy Shaw basieren auf Erhöhung eines Neurotransmitterspiegels im Gehirn durch Vorläufermischung aus Aminosäure(n) oder Cholin, Vitamin(en), evtl. Mineralien sowie Fruchtzucker, der Insulinauschüttung bewirkt, dadurch Blut-Gehirnschranke öffnet, was den Vorläufern Zugang zum Gehirn verschafft. Quelle: Zeitschrift "Wiener" 5/1990, S. 108, 3. bis 4. SpalteMost of Durk Pearson and Sandy Shaw's "designer foods" are based on increasing neurotransmitter levels in the brain through a precursor mixture of amino acids or choline, vitamins, possibly minerals and fructose, which causes insulin to be released, thereby opening the blood-brain barrier, which gives the precursors access to the brain. Source: "Wiener" magazine 5/1990, p. 108, 3rd to 4th column
Auch Saccharose bewirkt Insulinausschüttung.Sucrose also causes insulin release.
"Life Extension" von Durk Pearson und Sandy Shaw bei Warner Books (C) 1987, Aufl. unauff., S. 372, 1. Abs."Life Extension" by Durk Pearson and Sandy Shaw at Warner Books (C) 1987, unpublished edition, p. 372, 1st paragraph.
Um Azetvlcholin herzustellen, braucht das Gehirn Cholin oder Lezithin sowie Pantothensäure, dto., S. 187,1. Abs.To produce acetylcholine, the brain needs choline or lecithin as well as pantothenic acid, dto., p. 187, 1st paragraph.
Auch Cholinbitartrat und Cholinchlorid sind geeignet,
dto., S. 164,1. Abs.Choline bitartrate and choline chloride are also suitable,
ibid., p. 164,1. para.
Eine Mischung aus Cholin, Fruktose, Kupfer und den Vitaminen B3, B-5 und B-12 ist als "Gourmet Choline Cooler", ein "Designer-Food" zur Verbesserung von Intelligenz und Gedächtnis auf dem Markt in den USA, ob patentiert, ist mir unbekannt,
o. a. "Wiener", S. 110,1. Spalte, letzter Abs.A mixture of choline, fructose, copper and vitamins B3, B-5 and B-12 is on the market in the USA as "Gourmet Choline Cooler", a "designer food" to improve intelligence and memory, whether patented or not, is unknown to me.
oa "Wiener", p. 110, 1st column, last paragraph.
3 g Cholin haben geistige Leistungen von Studenten verbessert, o. a. "Life Extension", S. 164 oben3 g of choline improved the mental performance of students, see "Life Extension", p. 164 above
Dimethylaminoäthanolbitartrat erhöht den Azetylcholinspiegel im Gehini. Der aktive Bestandteil ist das Dimethylaminoäthanol.Dimethylaminoethanol bitartrate increases the level of acetylcholine in the brain. The active ingredient is dimethylaminoethanol.
o. a. "Life Extension", S. 484 Mitteo.a. "Life Extension", p. 484 middle
Azetylcholinvorläufer verschlimmern depressive Phase bei manisch-depressiver Psychose, o. a. "Life Extension", S. 187 "Warning"Acetylcholine precursors worsen depressive phase in manic-depressive psychosis, o. a. "Life Extension", p. 187 "Warning"
Der tägliche Bedarf eines Erwachsenen an Pantothensäure liegt bei 8 mg. Z. B. "Die grosse Vitamin und Mineralstofftabelle" von Prof. Dr. I. Elmadfa, Dipl. oec troph D. Fritsche. Prof Dr. H.-D. Cremer, Gräfe und Unzer Verlag (Jahr und Aufl. unauff., aber später als 1986), S. 21, 2. Abs.The daily requirement of pantothenic acid for an adult is 8 mg. For example, "The large vitamin and mineral table" by Prof. Dr. I. Elmadfa, Dipl. oec troph D. Fritsche. Prof. Dr. H.-D. Cremer, Gräfe und Unzer Verlag (year and edition unpublished, but later than 1986), p. 21, 2nd paragraph.
Eine erhöhte Aufnahme wasserlöslicher Vitamine ausser B-12 ist unschädlich. Pantothensäure ist wasserlöslich.An increased intake of water-soluble vitamins other than B-12 is harmless. Pantothenic acid is water-soluble.
dto.. S. 4,2. u. 3. Abs.dto.. p. 4,2. and 3. para.
Die Blut-Gehirn-Schranke schliesst sich nach Einlass einer bestimmten Menge Aminosäuren. "Brain Food" von Dr. Arthur Winter u. Ruth Winter, Verlag Bruno Martin, (C) 1988, S. 35, 2. Abs.The blood-brain barrier closes after a certain amount of amino acids have entered. "Brain Food" by Dr. Arthur Winter and Ruth Winter, Bruno Martin Publishing, (C) 1988, p. 35, 2nd paragraph.
Bekanntlich können Cholinverbindungen zu Gefäßerweiterung fuhren. Erweiterte Gefäße im Gehirn können durch den "Steal-Effect" eine schwächere Durchblutung anderer Gefäße im Gehirn bewirken. Quellen nicht mehr auffindbarIt is known that choline compounds can cause vasodilation. Dilated vessels in the brain can cause weaker blood flow to other vessels in the brain through the "steal effect". Sources can no longer be found
Rosskastanienextrakte wirken gefaßadstringierend.Horse chestnut extracts have a vascular astringent effect.
"Der Gesundheits-Brockhaus" unter Mitarbeit von Prof. Dr. M. Alexander etc., begr. von Prof. Dr. H. Mommseo. Bearb. Dr. med E. Hilka, 3. Aufl., F. A. Brockhaus, Wiesbaden 1984, S. 323"The Health Brockhaus" with the collaboration of Prof. Dr. M. Alexander etc., founded by Prof. Dr. H. Mommseo. Edited by Dr. med. E. Hilka, 3rd edition, F. A. Brockhaus, Wiesbaden 1984, p. 323
Ludwig Wilhelm Fehling, Stückenberg 43, 24226 HeikendorfLudwig Wilhelm Fehling, Stückenberg 43, 24226 Heikendorf
-3--3-
Die Abhängigkeit des Rauchers kommt durch das Rauchen bewirkte vermehrte Bildung von Azetylcholinrezeptoren im Gehirn, an die sich das Nikotin heftet, die nach Aufgeben des Rauchens nicht sofort wieder verschwinden und Entzugserscheinungen bewirken, wenn sie unbesetzt sind, zustande. Das Rauchen kann nicht aufgegeben werden und hat gesundheitliche Beeinträchtigungen zur Folge.The smoker's addiction is caused by the increased formation of acetylcholine receptors in the brain, which nicotine attaches to, and which do not disappear immediately after quitting smoking and cause withdrawal symptoms if they are not occupied. Smoking cannot be stopped and results in health problems.
Prof Dr. Roman Ferstl zitiert in "Therapie gegen den Qualm", 1. Spalte unten bis 5. Spalte oben aus "Kieler Nachrichten11 vom 20.6.92 in Beilage "KN-Joumal", S. 4Prof. Dr. Roman Ferstl quotes in "Therapy against smoke", 1st column bottom to 5th column top from "Kieler Nachrichten 11 of 20.6.92 in the supplement "KN-Joumal", p. 4
Problemproblem
die unbesetzten Azetylcholinrezeptoren müssen ohne die Aufnahme schädlicher Substanzen und ohne Nebenwirkungen besetzt werden.the unoccupied acetylcholine receptors must be occupied without the intake of harmful substances and without side effects.
Erfindunginvention
Das Problem wird durch Einnahme der Wirkstoffkombination, bei Rauchverlangen oder vorbeugend, gelöst. Nach Gelangen der Substanzen aus dem Verdauungstrakt ins Blut passiert Folgendes: Wenn Zucker enthalten ist bewirkt er eine Abgabe von Insulin ins Blut. Dies öffnet die Blut-Gehirn-Schranke, falls geschlossen. Wenn keine Zucker enthalten sind, ist die Öffnung nicht gesichert Die Substanzen gelangen ins Gehirn. Dort wird unter Verwendung von dekm Azetylcholinvorläufer und der Pantothensäure vermehrt Azetylcholin hergestellt. Das Dimethylaminoäthanol (wenn enthalten) führt ebenfalls zur Erhöhung des Azetylcholinspiegels. Unbesetzte, durch Rauchen neugebildete Rezeptoren können besetzt werden. Die Nikotinabhängigkeit vermindert sich. Einer Mangeldurchblutung im Gehirn durch "Steal-Effect" durch das Cholin im Blut wird durch die gefäßspannungserhöhende Wirkung z. B. des Rosskastanienextraktes als gefäßadstringierender Substanz (wenn dieser oder andere Angiotonika enthalten sind), bei Retardwirkung für längere Zeit vorgebeugt. Eine zu grosse Menge Aminosäuren oder die Blut-Gehirn-Schranke schließender Substanzen im Blut kann die Aufnahme der Vorläufer verhindern oder verzögern. In depressiver Phase manisch-depressiver Erkrankung soll die Mischung nicht genommen werden.The problem is solved by taking the combination of active ingredients when you feel like smoking or as a preventative measure. After the substances have passed from the digestive tract into the blood, the following happens: If sugar is present, it causes insulin to be released into the blood. This opens the blood-brain barrier if it is closed. If no sugar is present, the opening is not guaranteed. The substances reach the brain. There, acetylcholine is produced in greater quantities using the acetylcholine precursor and pantothenic acid. Dimethylaminoethanol (if present) also increases the acetylcholine level. Unoccupied receptors newly formed by smoking can be occupied. Nicotine dependence is reduced. Insufficient blood flow in the brain due to the "steal effect" caused by the choline in the blood is prevented for a longer period of time by the vascular tension-increasing effect of, for example, horse chestnut extract as a vascular astringent substance (if this or other angiotonics are present), with a sustained release effect. Too much amino acids or substances that close the blood-brain barrier in the blood can prevent or delay the absorption of the precursors. The mixture should not be taken during the depressive phase of manic-depressive illness.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20005297U DE20005297U1 (en) | 2000-03-21 | 2000-03-21 | Active ingredient combination against nicotine addiction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20005297U DE20005297U1 (en) | 2000-03-21 | 2000-03-21 | Active ingredient combination against nicotine addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE20005297U1 true DE20005297U1 (en) | 2000-07-27 |
Family
ID=7939166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE20005297U Expired - Lifetime DE20005297U1 (en) | 2000-03-21 | 2000-03-21 | Active ingredient combination against nicotine addiction |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE20005297U1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035092A1 (en) | 2001-10-26 | 2003-05-01 | Angiolab Inc. | Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
-
2000
- 2000-03-21 DE DE20005297U patent/DE20005297U1/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035092A1 (en) | 2001-10-26 | 2003-05-01 | Angiolab Inc. | Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| EP1438059A4 (en) * | 2001-10-26 | 2008-01-23 | Angiolab Inc | Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baird et al. | Repeated dose study of sucralose tolerance in human subjects | |
| CH654745A5 (en) | COMPOSITION FOR THE TREATMENT OF ALCOHOLIC AND DRUG ADDICTORS. | |
| Hamazaki et al. | Anti‐stress effects of DHA | |
| EP1414469A2 (en) | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
| DE3332429T1 (en) | MEDICINAL PRODUCT WITH ANTINICOTINE EFFECT AND METHOD FOR THE PRODUCTION THEREOF | |
| DE60214849T2 (en) | CHROMIUM / BIOTIN TREATMENT OF DYSLIPIDEMIA | |
| KR100404693B1 (en) | Phosphatidic Acid-Comprising Compositions | |
| DE3641495A1 (en) | AGENT TO INHIBIT DEVELOPMENT OF PATHOLOGICAL DRINKING ADDICTION | |
| DE60021247T2 (en) | CARNITINE AND INOSITOL PHOSPHATE CONTAINING A DIET ADDITIVE OR MEDICINAL PRODUCT | |
| DE10149108A1 (en) | Use of phosphatidylserine to treat Attention Deficit Disorder (ADHD) | |
| CN109452651A (en) | Endurance composition | |
| DE60032509T2 (en) | CHROMI-HISTIDINE COMPLEXES AS FOOD ADDITIVES | |
| Wenger et al. | Behavioral effects of cocaine and its interaction with d-amphetamine and morphine in rats | |
| Ilesanmi et al. | Effect of classic soft drink Coca-Cola as a solvent in the administration of tramadol and diazepam on biochemical and histological changes in liver and kidney | |
| DE20005297U1 (en) | Active ingredient combination against nicotine addiction | |
| Hemmingsen et al. | Delirium tremens and related clilnical states:| Psychopathology, cerebral pathophysiology and psychochemistry: A two‐component hypothesis concerning etiology and pathogenesis | |
| DE60114724T2 (en) | Blood flow improvers and preparations for the prevention or cure of thrombosis | |
| DE3414743C2 (en) | Food, chewing, swelling and fiber(s) with appetite suppressant | |
| DE19653354C1 (en) | Use of oligo:saccharide(s) | |
| LU501504B1 (en) | POWDERED FOOD SUPPLEMENT FOR MAKING A BEVERAGE | |
| DE9302109U1 (en) | Combination of active ingredients for smoking cessation | |
| DE60109651T2 (en) | CARNITINE AND HUPERZINE COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HYPERACTIVITY WITH ATTENTION DISORDERS IN CHILDREN | |
| DE69214979T2 (en) | New, dietary preparations based on phosphorus-lipid complexes and their use in sleep disorders | |
| DE3632791A1 (en) | AGENT AGAINST AGE CHANGES | |
| AT234277B (en) | Process for the manufacture of orally administrable iron preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 20000831 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20030506 |
|
| R157 | Lapse of ip right after 6 years |
Effective date: 20061003 |